GGrantIndex
← Search

TRIAL OF OCTREOTIDE IN HOSPITALIZED PATIENTS

$22,433M01FY2000RRNIH

University Of New Mexico, Albuquerque NM

Investigators

Linked publications & trials

Abstract

We hypothesize that early and repeated administration of octreotide, in addition to standard therapy with intravenous fluids and insulin, during the first 24 hours of hospitalization for DKA will result in a more rapid resolution of metabolic decompensation in DKA. These metabolic benefits may result in improved morbidity and mortality due to DKA, as well as a shorter stay in the medical intensive care unit and decreased medical costs.

View original record on NIH RePORTER →